Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line

Evan C. Meszaros1, Wissam Dahoud2, Sam Mesiano2 and Charles J. Malemud*

1Division of Rheumatic Diseases, Department of Medicine, Arthritis Research Laboratory, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
2Department of Reproductive Biology, Case Western Reserve University School of Medicine, Cleveland, OH, USA

Abstract

Two immortalized human juvenile chondrocyte cell lines, T/C28a2 and C28/I2, were employed to determine the extent to which recombinant human (rh) IL-6 or rh-TNF-α increased the production of matrix metalloproteinase-9 (MMP-9). The effect of rhIL-6 on neutrophil gelatinase-associated lipocalin (NGAL) was also assessed. Although C28/I2 chondrocytes incubated with rhIL-6 (50 ng/ml) increased MMP-9 production which could not be mimicked by the T/C28a2 chondrocyte line, the effect of rhTNF-α on MMP-9 was more robust than with rhIL-6. The combinations of rhIL-6 and soluble IL-6 receptor-α (sIL-6Ra) or rhIL-6 and tocilizumab (TCZ), a fully-humanized recombinant monoclonal antibody that neutralizes the interaction between IL-6 and IL-6R significantly reduced MMP-9 production by C28/I2 chondrocytes. However, TCZ had no effect on rhTNF-α-induced MMP-9 production. By contrast, rhIL-6 did not increase the production of NGAL by C28/I2 chondrocytes although the number of NGAL-positive cells was significantly reduced by sIL-6Rα compared to its control group, but not by the combination of rhIL-6 plus TCZ compared to rhIL-6. In summary, these results showed that rhIL-6 stimulated the production of MMP-9, but not NGAL, in the C28/I2 chondrocyte line. TCZ or sIL-6Ra suppressed rhIL-6-induced MMP-9 production.

Introduction

Matrix metalloproteinase-9 (MMP-9; gelatinase B; 92 kDa gelatinase; 92 kDa type IV collagenase) is a critical MMP in mediating the progression of various arthritic conditions [1]. MMP-9 has the capacity to degrade several articular cartilage extracellular matrix (ECM) proteins, including aggrecan, link protein, and type II collagen, all of which help maintain normal cartilage biomechanical functions [1]. Importantly, in various types of arthritis, chondrocyte MMP-9 gene expression is significantly up-regulated in response to the elevated levels of pro-inflammatory cytokines in the synovial fluid milieu, exemplified by interleukin-6 (IL-6), IL-1β, IL-17, and tumor necrosis factor-α (TNF-α) [1-3].

To probe the contribution of each of those cytokines to MMP-9 gene expression by articular chondrocytes in vitro would generally require that specific inhibitors for each of them be individually tested. In that regard, the effect of IL-1β or TNF-α blockade on MMP-9 synthesis was previously reported with the results showing that IL-1 receptor antagonist or TNF-α blocking monoclonal antibodies inhibited MMP production [4]. However, the contribution of IL-6 to MMP-9 production by cultured human chondrocytes remains to be fully elucidated. Therefore, to achieve this objective, the extent to which tocilizumab (TCZ), a recombinant fully humanized IgG1(κ) monoclonal antibody that neutralizes the interaction between IL-6 and the IL-6 receptor-α (IL-6Ra) [5] inhibits recombinant human (rh)IL-6-mediated MMP-9 production was determined in the immortalized human juvenile T/C28a2 and C28/I2 chondrocyte lines. These human chondrocyte lines were employed for this analysis because they had been previously shown to express cartilage-specific extracellular matrix protein genes [6,7]. T/C28a2 and C28/I2 chondrocytes also expressed several other molecules characteristic of authentic human chondrocytes, most notably the molecular signature SOX9 gene, considered the “master” transcriptional regulator of several cartilage-specific genes as the type II collagen (COL2A1) gene and the aggrecan (AGRN) gene [6-8].

The effect of rhIL-6 on the synthesis of chondrocyte-derived neutrophil gelatinase-associated lipocalin (NGAL) was also evaluated. The rationale for analyzing NGAL production by C28/I2 chondrocytes stemmed from our previously reported finding that chondrocytes obtained from human osteoarthritis knee cartilage synthesized NGAL in response to IL-1β [9]. In addition, we showed that NGAL in synovial fluids obtained from patients with end-stage osteoarthritis was found in a complex with MMP-9. Moreover, we proved that the MMP-9/NGAL complex preserved MMP-9 activity by demonstrating that this complex prevented MMP-9 from being degraded, thus preserving MMP-9 activity [10].

Correspondence to: Charles J. Malemud, Division of Rheumatic Diseases, Department of Medicine, University Hospitals Case Medical Center, Foley Medical Building, 2061 Cornell Road, Rm. 207, Cleveland, OH 44106-5076, Tel: (216) 844-7846; Mobile: (216) 536-1945 (Preferred); Fax: (216) 844-2288, E-mail: cjm4@cwru.edu

Keywords: IL-6, tocilizumab, matrix, metalloproteinase-9, C28/I2 immortalized human chondrocyte

Received: July 08, 2015; Accepted: August 04, 2015; Published: August 08, 2015
Materials and methods

Human chondrocyte cell lines

The immortalized human juvenile chondrocyte cell lines, T/C28a2 and C28/I2, were obtained from the laboratory of Professor Mary B. Goldring [Hospital for Special Surgery/Weill Medical College of Cornell University (New York, New York)].

PANC-1

PANC-1, a line of pancreatic carcinoma cells, was obtained from the American Type Culture Collection (Manassas, VA).

MMP-9 ELISA/NGAL ELISA, anti-MMP-9/anti-NGAL Immunocytochemistry (ICC)

An ELISA kit containing anti-MMP-9 antibody was purchased from Aviva Systems (San Diego, CA). An ELISA kit for the detection of NGAL was purchased from Pierce Biotechnology (Rockford, IL). The anti-MMP-9 antibody and anti-NGAL antibody employed for ICC were purchased from Abcam (Cambridge, MA). The human anti-MMP-9 antibody used for ICC was a rabbit polyclonal antibody produced against a rat recombinant fragment of the MMP-9 catalytic domain. According to the manufacturer, this anti-MMP-9 antibody is reactive with both pro-MMP-9 and activated MMP-9. For the NGAL ICC, the immunogen used to produce the anti-NGAL antibody was a synthetic peptide corresponding to the 38-53 amino acid sequence, LPQPFWTERFOGWRFW located at the N-terminus of rat NGAL.

Recombinant human (rh) IL-6, rhTNF-α and soluble IL-6 Receptor-α (sIL-6Rα)

The cytokines, rhIL-6, and rhTNF-α, and soluble IL-6Ra (sIL-6R) were purchased from various commercial vendors.

Tocilizumab (TCZ)

Tocilizumab (TCZ) was obtained through a research contract between Genentech/Roche Group (South San Francisco, CA) and Case Western Reserve University.

Human T/C28a2, C28/I2 Chondrocytes and PANC-1

T/C28a2 or C28/I2 chondrocytes were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 medium (1:1 ratio) supplemented with 10% (v/v) fetal bovine serum (FBS). PANC-1 was maintained in continuous culture according to instructions provided by the American Tissue Culture Collection.

Experimental Conditions for MMP-9/NGAL ELISA and MMP-9/NGAL ICC

T/C28a2 or C28/I2 chondrocytes (3 × 10^5 cells/ml, ELISA; 10^5 cells/ml, ICC) were incubated in DMEM/F12 (1:1) containing 10% (v/v) fetal bovine serum (FBS). PANC-1 was maintained in continuous culture according to instructions provided by the American Tissue Culture Collection.

Results

MMP-9 production is increased by rhIL-6 and rhTNF-α: Effect of sIL-6R and TCZ

A standard curve was produced for the MMP-9 ELISA which showed that the concentration of MMP-9 as a function of OD_{450} was linear (Figure 1). This standard curve was used to calculate the amount of MMP-9 (pg/ml) produced by T/C28a2 or C28/I2 chondrocytes or by PANC-1 cells using direct interpolation of the OD_{450} measurements performed on the various cell lysates.

Incubation of C28/I2 chondrocytes, but not T/C28a2 chondrocytes, with rhIL-6 increased MMP-9 production. MMP-9 production was reduced when rhIL-6 was combined with either sIL-6R or TCZ (Figure 2). Although rhIL-6 also increased MMP-9 in PANC-1 cells, the combination of rhIL-6 plus TCZ did not inhibit MMP-9. Of note, the effect of rhTNF-α on MMP-9 production by T/C28a2 or C28/I2 chondrocytes was far more robust than with rhIL-6 (Figure 2). However, the combination of rhTNF-α and TCZ had no effect on MMP-9 production by T/C28a2 chondrocytes whereas the combination of
Meszaros EC (2015) Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line

Effect of TCZ concentration on MMP-9 production by C28/I2 chondrocytes

We next examined the effect of varying the concentration of TCZ between 200 ng/ml and 800 ng/ml on MMP-9 production by C28/I2 chondrocytes in response to rhIL-6 (50 ng/ml). Although the average of duplicate determinations from the MMP-9 ELISA showed that TCZ (200 ng/ml) reduced rhIL-6-induced MMP-9 after 1 hr by Δ=-16% (Figure 3) this difference did not reach statistical significance. However, TCZ at concentrations ranging from 400 ng/ml to 800 ng/ml significantly reduced MMP-9 after 1 hr (Figure 3). Furthermore, the reduction in MMP-9 in response to the combination of rhIL-6 plus TCZ was sustained after 4 hrs (Figure 3). Of note, concentrations of TCZ greater than 200 ng/ml did not increase its inhibitory effect on MMP-9 production at 1 hr (Figure 3) or at 4 hrs (Figure 3). The result of the chi-square analyses for all of the group comparisons is summarized in Table 1.

ICC analysis of MMP-9 production by C28/I2 chondrocytes and PANC-1

MMP-9 production was also analyzed by ICC using an anti-MMP-9 antibody that is reactive with both pro-MMP-9 and activated MMP-9. The photomicrograph in Figure 4A shows the appearance of the negative C28/I2 chondrocyte control for MMP-9. This image was arrived at by processing the cells for ICC but without applying primary anti-MMP-9 antibody. The other photomicrographs (Figure 4B) show C28/I2 chondrocytes from the ‘no additions’ control group which were identified by Metamorph as MMP-9-positive (arrows) in 6 regions of the cover slip encompassing the microscopic fields enumerated for the ICC analysis.

Incubation of PANC-1 cells with rhIL-6 increased MMP-9 to a similar extent as was found for C28/I2 chondrocytes (Figure 2). However, whereas the combination of rhIL-6 plus sIL-6R reduced MMP-9 to an undetectable level in C28/I2 chondrocytes, the combination of rhIL-6 plus sIL-6R had no effect on MMP-9 produced by PANC-1.

In contrast, PANC-1 cells incubated with PMA (30.7 ng/ml), serving as the positive control for MMP-9 production [13], substantially increased MMP-9 production, compared to its DMSO-control group (Figure 2).

Table 1. χ² Analysis: Effect of TCZ on MMP-9 Production by C28/I2 Chondrocytes.

| Group | [TCZ] | 60 min | 4 hrs |
|-------|-------|--------|-------|
| 1     | 200 ng/ml | χ²=0.38; p = 0.54 | χ²=0.6; p = 0.002* |
| 2     | 400 ng/ml | χ²=10.1; p = 0.001* | χ²=18.7; p = 1.5 × 10⁻⁸* |
| 3     | 600 ng/ml | χ²=3.96; p = 0.046* | χ²=17.6; p = 2.6 × 10⁻⁷* |
| 4     | 800 ng/ml | χ²=5.16; p = 0.02* | χ²=17.6; p = 2.6 × 10⁻⁷* |

Ratio of [TCZ] to [rhIL-6]: 4:1; 8:1; 12:1; 16:1

*p-value for significance was <0.05
Meszaros EC (2015) Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line

The ICC of anti-MMP-9 antibody-positive C28/I2 chondrocytes treated with rhIL-6 (50 ng/ml) for 24 hrs is shown in Figure 5 and compared to C28/I2 chondrocytes in the "no additions" control or 10% FBS control group. The quantitative analysis showed that rhIL-6 significantly increased the number of anti-MMP-9 antibody positive chondrocytes compared to the "no additions" control group [i.e. DMEM/F12 (1:1) containing 0.5% FBS; (p=1.23 × 10^-7)]. As a further determination regarding the specificity of the rhIL-6 effect on C28/I2 chondrocyte MMP-9 production, PANC-1 cells were also incubated with rhIL-6 (50 ng/ml) for 24 hrs. The number of MMP-9-positive PANC-1 cells was not significantly altered by rhIL-6 ("no additions" control, Arbitrary Units, 17.3 ± 0.28; rhIL-6, 15.5 ± 0.78; mean ± SD, n=5; p=0.67).

C28/I2 chondrocytes maintained in DMEM/F12 (1:1) containing 10% FBS for 24 hrs also increased the number of MMP-9-positive chondrocytes compared to the "no additions" control containing 0.5% FBS (p<2 × 10^-3). This result provided substantive justification for maintaining C28/I2 chondrocytes in 0.5% FBS for determining MMP-9 production in the various treatment groups.

Although C28/I2 chondrocytes incubated with rhIL-6 alone had a significantly increased number of MMP-9-positive chondrocytes compared to the "no additions" control group, the combination of rhIL-6 plus sIL-6R also significantly increased the number of MMP-9-positive chondrocytes compared to sIL-6R (p=3.1 × 10^-9) (Figure 6), whereas sIL-6R alone significantly reduced the number of MMP-9-positive chondrocytes compared to rhIL-6 (p=2.2 × 10^-8). This was also the case for the rhIL-6 plus TCZ group when compared to rhIL-6 (p=9.7 × 10^-10) (Figure 6). Importantly, TCZ alone had no significant effect (p=0.07) on chondrocyte MMP-9 positivity compared to rhIL-6.

**ICC analysis of NGAL production by C28/I2 chondrocytes**

The number of NGAL-positive cells was significantly reduced (F=48.86; p=4.3 × 10^-4) by sIL-6R compared to the "no additions" control group as well as by the combination of rhIL-6 plus TCZ (F=19.00; p=4.7 × 10^-3) (Figure 7). By contrast, none of the other incubation conditions, altered NGAL production (Figure 7). Notably, rhIL-6 plus TCZ failed to significantly reduce NGAL compared to rhIL-6. In general, the ICC analysis of the various treatment groups for NGAL-positive chondrocytes mirrored results obtained with the NGAL ELISA (data not shown).

**Discussion**

The principal objectives of this study were 1) to determine the extent to which rhIL-6 stimulated MMP-9 and NGAL production by immortalized human juvenile chondrocyte lines; and 2) to determine...
whether sIL-6R or TCZ, the latter a fully humanized IgG1(κ) monoclonal antibody which neutralizes the interaction between IL-6 and IL-6Ra, augmented or inhibited MMP-9 and/or NGAL.

The principal result of MMP-9 ELISA was that rhIL-6 alone stimulated MMP-9 production by C28/I2, but not T/C28a2 immortalized human chondrocytes. In the MMP-9 ELISA, the combination of rhIL-6 and sIL-6R significantly decreased MMP-9 production in C28/I2 chondrocytes and most importantly, the combination of rhIL-6 plus TCZ also reduced MMP-9 compared to rhIL-6. In analyzing both the MMP-9 ELISA and anti-MMP-9 ICC results, we found that the combination of rhIL-6 plus TCZ reduced MMP-9, but TCZ by itself had no effect on chondrocyte-derived MMP-9 compared to rhIL-6. These data strongly suggested that neutralizing the interaction between rhIL-6 and IL-6R with TCZ in vitro reduced C28/I2 chondrocyte MMP-9 production. However, it remains to be determined the extent to which any of the various treatment groups altered either or both pro-MMP-9 and/or activated MMP-9 because the anti-MMP-9 antibody used in the ICC analysis does not distinguish between the two enzyme forms. Thus, we have come to recognize this as an important limitation of this study.

It is well known that IL-6 activates the JAK/STAT pathway in many cell types [5], including chondrocytes [4,11]. In that regard, only two previously published in vitro studies were designed to correlate MMP-9 production per se with STAT protein phosphorylation. In one of these studies, Dechow et al. [15] indicated that there appeared to be a “strong” relationship between MMP-9 gene expression and the level of tyrosine phosphorylated STAT3 (termed STAT3c) in primary breast cancer specimens. In the other study, Kothari et al. [16] showed that IL-6-induced macrophage MMP-9 gene expression was mainly dependent on p-ERK1/2 although MMP-9 gene expression was also inhibited by a JAK-dependent product, identified as IL-10. In view
of these results, future in vitro experiments should determine the precise relationship between activation of STAT proteins by rhIL-6 and activation of pro-MMP-9 gene activity as well as identifying any cofactors that may also be involved in pro-MMP-9 gene expression [17]. In that regard, it is generally agreed that these studies will have to employ quantitative PCR for assessing MMP-9 gene expression as well as gelatin-impregnated zymography to determine the extent to which pro-MMP-9 is activated under the various culture conditions. In fact, “gelatin-zymography” will be critical to this assessment in the analysis of pro-MMP-9 activation [18]. This is due to the fact that intracellular processing of latent pro-MMP-9 can produce different forms of active gelatinase, with molecular sizes ranging from 64 kDa to 82 kDa.

Finally, rhIL-6 failed to stimulate NGAL production in C28/I2 chondrocytes. This result contrasted with previous results obtained for NGAL production by human osteoarthritis chondrocytes in response to rhIL-1β [9]. This difference may merely represent a differential response of human chondrocytes to IL-1β versus IL-6 or differences between human OA chondrocytes and the C28/I2 human chondrocyte line.

It noteworthy that Zerenga et al. [19] did not find any evidence for NGAL protein in either normal human adult articular cartilage or tracheal cartilage or for that matter, any NGAL produced by cultured rat embryo chondrocytes. However, NGAL protein synthesis could be induced in the rat chondrocyte cultures by lipopolysaccharide (LPS) [19], indicating that the NGAL gene was up-regulated by LPS and potentially by other pro-inflammatory mediators.

Changes in NGAL production were also evaluated following treatment of C28/I2 chondrocytes with rhIL-6 plus sIL-6 or rhIL-6 plus TCZ. Thus, whereas the combination of rhIL-6 and TCZ inhibited MMP-9 production compared to rhIL-6 alone, the results of the anti-NGAL antibody ICC showed that rhIL-6 plus TCZ did not significantly affect NGAL production compared to rhIL-6, although rhIL-6 plus TCZ significantly reduced NGAL compared to the “no additions” control group.

Finally, the results of this in vitro study could have substantive implications for potentially employing TCZ to regulate rhIL-6-induced MMP-9 and/or NGAL production by articular cartilage in various arthritic conditions. Since MMP-9 forms a complex with NGAL with the MMP-9/NGAL complex maintaining MMP-9 in its activated state [10], the putative inability of TCZ to effectively regulate C28/I2 chondrocyte NGAL production may have significance for future translational research. Although sIL-6R as well as the combination of rhIL-6 plus TCZ significantly dampened NGAL production compared to the “no additions” control group, the overall results suggested that employing therapeutic levels of TCZ in arthritic disorders might be most effective for regulating elevated levels of chondrocyte NGAL when NGAL is over-produced in response to the combined effects of other pro-inflammatory cytokines implicated in arthritis which include, IL-1β [4], TNF-α [4], IL-17A [20] and OSM [21].

Conflicts of interest statement
The authors declare no conflicts of interest.

References
1. Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11: 1696-1701. [Crossref]
2. Burragre PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11: 529-543. [Crossref]
3. Martel-Pelletier J, Welsch DJ, Pelletier JP (2001) Metalloproteinases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 15: 805-829. [Crossref]
4. Malemud CJ (2013) Immunotherapies and rheumatoid arthritis-Introduction. J Clin Cell Immunol 6(6):001.
5. Shetty A, Hanson R, Korsten P, Shawagfeh M, Arami S, et al. (2014) Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther 8: 349-364. [Crossref]
6. Kakonen Y, Tan L, Robbins JR, Goldring MB (2002) Proteoglycan production by immortalized human chondrocyte cell lines cultured under conditions that promote expression of the differentiated phenotype. Arch Biochem Biophys 383: 79-90. [Crossref]
7. Goldring MB (2004) Culture of immortalized chondrocytes and their use as models of chondrocyte function. Methods Mol Med 100: 37-52. [Crossref]
8. Finger F, Schirle C, Zien A, Gebhard P, Goldring MB, et al. (2003) Molecular phenotyping of human chondrocyte cell lines T-C-28a2, T-C-28a4, and C-28/I2. Arthritis Rheum 48: 3395-3403. [Crossref]
9. Gupta K, Shukla M, Malemud CJ, Cowland J, Haqmi TM (2006) Neutrophil gelatinase-associated lipocalin (NGAL) is produced by IL-18-stimulated human osteoarthritic chondrocytes and protects MMP-9 from degradation. Osteoarthritis Cartilage 14 Suppl B: S87-S88.
10. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqmi TM (2007) Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rhenum 56: 3326-3335. [Crossref]
11. Aida Y, Honda K, Tanigawa S, Nakayama G, Matsumura H, et al. (2012) IL-6 and soluble IL-6 receptor stimulate the production of MMPs and their inhibitors via JAK-STAT and ERK-MAPK signalling in human chondrocytes. Cell Biol Int 36: 367-376. [Crossref]
12. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, et al. (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclase-like cell formation. J Bone Miner Res 11: 88-95. [Crossref]
13. Haq M, Shaiel AE, Zervos EE, Rosemurgy AS (2000) In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organs. Int J Surg Invest 1: 459-465. [Crossref]
14. Rose-John S, Waetzig GH, Scheller J, Grötzinger J, Seegert D (2007) The IL-6/IL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11: 613-624. [Crossref]
15. Dechow TN, Pedrizzini L, Leitch A, Leslie K, Gerald WL, et al. (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 101: 10602-10607. [Crossref]
16. Kothari P, Pestana R, Mesroaou R, Elchaki R, Khan KM, et al. (2014) IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages. J Immunol 192: 349-357. [Crossref]
17. Malemud CJ, Pearlman E (2009) Targeting JAK/STAT signaling pathway in inflammatory diseases. Curr Signal Transduct Ther 4: 201-221.
18. Toth MI, Sohal A, Fridman R (2012) Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol 878: 121-135. [Crossref]
19. Zerenga B, Carmelli S, Michelis B, Cancedda R, Cancedda RD, et al. (2000) Expression of NRL/NGAL (neu-related lipocalin/neutrophil gelatinase-associated lipocalin) during mammalian embryonic development and in inflammation. Eur J Cell Biol 79(3): 165-172. [Crossref]
Meszaros EC (2015) Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line

20. Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, et al. [2009] Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, oncostatin M and response to biologic therapies. *Arthritis Res Ther* 11(4): R113. [Crossref]

21. Li WQ, Dehnade F, Zafarullah M (2001) Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. *J Immunol* 166(5): 3491-3498. [Crossref]

Copyright: ©2015 Meszaros EC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.